Understanding the FDA's Updated Tysabri Prescribing Information

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Pharmaceutical Risk

If you or a loved one is taking Tysabri, understanding the risk of progressive multifocal leukoencephalopathy (PML) is critical. Decades of pharmacovigilance have established PML as a rare but serious adverse event associated with this therapy. This page summarizes the key elements of the current FDA prescribing information, including risk factors and monitoring recommendations.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn disease. Its prescribing information contains a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus. PML typically leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning identifies three established risk factors for PML in Tysabri-treated patients: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors must be weighed against expected benefit when initiating and continuing therapy. PML is a demyelinating disease of the central nervous system that results from reactivation of latent JC virus in immunocompromised individuals. Clinical presentation can include progressive neurological deficits such as cognitive decline, motor weakness, visual disturbances, and speech difficulties. Diagnosis typically relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid. The disease course is often rapid and devastating, with most patients experiencing permanent disability or death.

Mechanism of Action and Risk Factors

The mechanistic link between Tysabri and PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs normal immune surveillance of the brain. Without adequate trafficking of T cells and other immune cells, JC virus can reactivate and proliferate unchecked, leading to PML. The risk is highest in patients who are seropositive for anti-JCV antibodies, have received Tysabri for more than two years, or have a history of immunosuppressant use. FDA adverse event reports from the FAERS database list PML as a frequently reported serious adverse event associated with Tysabri. Other commonly reported events include fatigue, multiple sclerosis relapse, headache, gait disturbance, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These reports underscore the importance of vigilant monitoring for neurological symptoms that could signal PML.

Adequacy of Warnings and Legal Implications

The adequacy of warnings regarding Tysabri and PML is a central consideration for affected patients and their families. The boxed warning is prominently displayed in the prescribing information and clearly states the increased risk of PML, the need for monitoring, and the requirement to withhold Tysabri at the first sign or symptom suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which mandates regular patient evaluations and reporting of PML cases to the manufacturer (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers and patients were adequately informed about the magnitude of risk, particularly in the context of evolving understanding of risk factors over time. For patients in Texas who have developed PML after Tysabri treatment, attorney-related considerations include the statute of limitations for filing a product liability or medical malpractice claim. In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. This timeline can be complex in PML cases because the disease may have a gradual onset, and the connection to Tysabri may not be immediately apparent. Patients and their families should consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadlines and preserve their legal rights.

Timeline of Exposure and Monitoring

The timeline between Tysabri exposure and documented harm is critical for both medical management and legal action. PML typically develops after months to years of Tysabri treatment, with risk increasing significantly after two years of therapy. The prescribing information recommends evaluating patients three months after the first infusion, six months after the first infusion, and every six months thereafter, as well as for at least six months after discontinuing Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This monitoring schedule is designed to detect PML early, but delays in diagnosis can occur if symptoms are attributed to multiple sclerosis relapse or other causes. In summary, Tysabri-associated PML is a serious and often fatal condition with well-documented risk factors and a clear mechanistic basis. The FDA-mandated warnings and monitoring program aim to mitigate risk, but affected patients may still face significant harm. For those in Texas, understanding the statute of limitations and consulting with legal counsel is essential to pursue any claims related to inadequate warnings or failure to monitor. The evidence underscores the importance of timely diagnosis and the need for ongoing vigilance in patients receiving Tysabri.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Texas?

In Texas, the statute of limitations for personal injury claims is generally two years from the date the injury was discovered or reasonably should have been discovered. For PML cases, this timeline can be complex due to gradual onset and delayed diagnosis. It is crucial to consult an attorney experienced in pharmaceutical litigation to determine the applicable deadlines.

What are the risk factors for developing PML while on Tysabri?

The three established risk factors are: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. These factors are detailed in the prescribing information (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.